Pfizer: Turning The Corner (Rating Upgrade)

JHVEPhoto Pfizer (NYSE:PFE) (NEOE:PFE:CA) hasn't been a favorite biopharma play due to the unsustainable Covid boost, leading to a period of sales declines. The stock appears to have hit bottom and could get a push higher from the bird flu fears, though the company is now too focused on cost cuts. My investment thesis is now slightly bullish on the stock due to the cheap valuation.   Source: Finviz Hitting Bottom The key to the investing story is removing the risk of additional Covid sales downside. Pfi ...